Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RXRX   2:31:21 PM EDT
25.78
+1.52 (+6.26%)
Earnings Announcements

Recursion Pharmaceuticals - Q2 Revenue $2.5 Mln Versus To $186,000 A Year Earlier

Published: 08/13/2021 12:03 GMT
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) - Recursion Pharmaceuticals - Qtrly Net Loss per Share of Class A and B Common Stock, Basic and Diluted $0.31.
Revenue is expected to be $2.68 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $5.2 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.